Dear Sir/Madam,

See these links may be useful for you.

1) HBV/HIV Co-Infection Management and Treatment www.hepb.org/.../hbv_hiv_co-infection_treatment_g...Traduire cette pageHBV/HIV Co-infection. Management and Treatment. There are two main reasons for considering HBV therapy as a priority in HBV/HIV co-infected patients:.

2) Treatment of hepatitis C virus infection in the HIV-infected ...www.uptodate.com/.../treatment-of-hepatitis-c-virus-i...Traduire cette page13 janv. 2016 - This topic will address the management of the HIV/HCV-coinfected ... Top. McGovern BH. Hepatitis C in the HIV-infected patient. J Acquir ...

3) Best Practices in the Management of HCV/HIV Coinfection www.clinicaloptions.com › ... › CCO Slideset

 Traduire cette page6 janv. 2014 - Jürgen K. Rockstroh, MD, provides a concise update on screening strategies and emerging treatment options for patients with HIV/HCV ...

4) Managing HIV/hepatitis C co-infection in the era of direct ...bmcmedicine.biomedcentral.com/.../1741-7015-11-2...

 Traduire cette page de JK Rockstroh - ‎2013 - ‎Cité 32 fois - ‎Autres articles

Managing HIV/hepatitis C co-infection in the era of direct acting antivirals ..... Response rates at Week 16 were best for previous relapsers (with 90%

Dear Khashayar Hesamizadeh

Greetings,

Please find the attached file may useful for you ,

Best Regards

I am not a physician, but considering the latest successes of HCV treatment and insights into establishment of HIV reservoirs, what should really stick to the most recent guidelines. Reference number 2 from Nouhoum Bouare is therefore a good start. You can also have a look at the European AIDS clinical society guidelines that I have attached. As far as I can tell (again not being a physician), start ART as early as possible in case the patients are not already on treatment and then start to treat HCV 6 to 8 weeks later with a compatible regimen.

Best,

Michael

Hi Khashayar,

The coinfection HCV/HIV is one of major public health problems. The long-term impact of HCV infection is highly variable, ranging from minimal histological changes to extensive fibrosis and cirrhosis with or without hepatocellular carcinoma (HCC) associated with HIV-related immune destabilization are responsible of a body weakness. I send you some important documents (slides and guidelines 2015) in this coinfection by the attached file.

1) Daclatasvir + Sofosbuvir in HCV GT 1-4 and HIV CoinfectionALLY-2 Study. WylesDL, et al. N EnglJ Med. 2015;373:714-25.

2) EASL Recommendations on Treatment of Hepatitis C 2015. European Association for the Study of the Liver. Guidelines, Journal of Hepatology 2015 vol. 63, 199-236.

All the best,

I suggest the study of following paper:

Fri, Jan 29, 2016, 3:16AM EST - US Markets open in 6 hrs and 14 mins

European Commission Approves Daklinza (daclatasvir) for the Treatment of Genotype 1, 3 and 4 Chronic Hepatitis C Patients with HIV Coinfection, Advanced Cirrhosis and Post-liver Transplant Recurrence of HCV

it is available online and it could be useful for answering your question.I paste here some paragraph of this article:

Bristol-Myers Squibb Company (BMY) announced today that the European Commission has approved Daklinza for the treatment of chronic hepatitis C (HCV) in three new patient populations. The expanded label allows for the use of Daklinza in combination with sofosbuvir (with or without ribavirin, depending on the indication and HCV genotype) in HCV patients with decompensated cirrhosis, HIV-1 (human immunodeficiency virus) coinfection, and post-liver transplant recurrence of HCV in all 28 Member States of the European Union.

“The European Commission’s approval of these new indications for Daklinza is an important step forward for a significant group of patients with chronic hepatitis C who are still in need of treatment options that can deliver high cure rates,” said Douglas Manion, M.D., head of Specialty Development, Bristol-Myers Squibb. “The complex clinical considerations for physicians treating HCV/HIV coinfected patients and patients with cirrhosis, decompensated cirrhosis or post-transplant recurrence of HCV reinforces the vast diversity of this disease, and we have worked hard to continue to identify and address those patients who require additional solutions for cure.”

Daklinza is contraindicated in combination with medicinal products that strongly induce CYP3A and P-glycoprotein transporter, as this may lead to lower exposure and loss of efficacy of Daklinza. Daklinza must not be administered as a monotherapy.

Daklinza is already approved by the European Commission for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic HCV infection in adults, and the Daklinza + sofosbuvir regimen is the only approved 12-week, all-oral treatment for genotype 3 HCV patients without cirrhosis. The new indications are based on data from the ALLY-1 clinical trial (in post-transplant patients and patients with advanced cirrhosis) and ALLY-2 clinical trial (in HIV-coinfected patients). The recommended treatment regimens and durations are as follows:..............